On July 3, Lianhuan Pharmaceutical(600513) announced that the company has recently conducted a specific object survey with a number of investment institutions. The event was held in Beijing on July 2, 2025, and the participating units included China Asset Management, China Canada Fund and Shibei Investment. The company's director and general manager Niu Ben and the director of the board office Ge Kai received investors and introduced the company's development history, technical cooperation and the progress of the projects under research.

The LH-1801 project mentioned in the announcement is an SGLT2 inhibitor jointly developed by the company and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The project has now entered the Phase III clinical trial stage. It is expected that key data will be obtained in the first quarter of next year and an application for listing will be submitted to the National Medical Products Administration in 2026.

In addition, the LH-1801 project chose to conduct a head-to-head experiment with dapagliflozin, which has a higher market share. Based on the previous research data, it showed advantages in pharmacodynamic activity, and its market competitiveness was emphasized. According to the data of the International Diabetes Federation, the number of diabetes patients in China is huge, which provides a broad space for the market promotion of this project.

The company has a diversified pipeline of products under development, covering hormones, urogenital, antihistamines, cardiovascular and other fields. In addition to LH-1801, there are also LH-1901 for the treatment of chronic obstructive pulmonary disease and LH-1802 for the treatment of acute myeloid leukemia. The company attaches great importance to R&D investment. According to the company's financial budget, the R&D expenses in 2025 will be 229 million yuan. This shows that the company continues to increase its investment in innovative drugs and commitment to R&D.

In the first quarter of 2025, Lianhuan Pharmaceutical achieved revenue of 628 million yuan and net profit attributable to shareholders of the parent company of 23.06 million yuan.

https://finance.eastmoney.com/a/202507033447509161.html